<DOC>
	<DOCNO>NCT00240929</DOCNO>
	<brief_summary>A total 150 child meet entry criterion randomize 1:1 receive one follow treatment sequence A B .</brief_summary>
	<brief_title>A Phase II Randomized , Double-Blind , Two-Period Cross-Over Study Evaluate Pharmacokinetics , Safety Tolerability Liquid Formulation Palizvizumab ( MEDI-493 , Synagis )</brief_title>
	<detailed_description>Phase II , Double-blind , two-period , cross-over study conduct 20 site U.S. A total 150 child meet entry criterion randomize 1:1 receive one follow treatment sequence : Sequence A ( single dose liquid formulation Study Day 0 single dose lyophilize formulation Study Day 30 ) Sequence B ( single dose lyophized forumation Study Day 0 single dose liquid formulation Study Day 30 ) . Children follow adverse event 30 day injection study drug blood collect determination palivizumab concentration serum .</detailed_description>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Palivizumab</mesh_term>
	<criteria>The child must bear great equal 35 week gestation great equal 6 month age time randomization ( child must randomize 6month birthday ) The child 's parent legal guardian must provide write informed consent ; The child must able complete followup visit Study Days 30 60 within protocol specify window ( ±2 day ) Parent/legal guardian patient available telephone access . Be hospitalize ; Birth hospitalization &gt; 6 week duration ; Be receive mechanical ventilation time study entry ( include CPAP ) ; Bronchopulmonary dysplasia ( BPD ) , define history prematurity associate chronic lung disease oxygen requirement &gt; 28 day ; Congenital heart disease ( CHD ) . ( Children medically surgically correct [ close ] patent ductus arteriosus CHD may enrol . ) Known renal impairment , hepatic dysfunction , chronic seizure disorder , immunodeficiency ; Any follow laboratory finding blood obtain within 7 day prior study entry : BUN creatinine &gt; 1.5´ upper limit normal age AST ( SGOT ) ALT ( SGPT ) &gt; 1.5´ upper limit normal age hemoglobin &lt; 9.0 gm/dL white blood cell count &lt; 4,000 cells/mm3 platelet count &lt; 110,000 cells/mm3 Acute illness progressive clinical disorder ; History recent difficult venous access ; Active infection , include acute RSV infection ; Previous reaction IGIV , blood product , foreign protein ; Received within past 120 day currently receive IGIV , immunoglobulin product , investigational agent ; Have ever receive palivizumab ; Currently participate investigational study ; Previously participate investigational study RSV vaccines monoclonal antibody .</criteria>
	<gender>All</gender>
	<minimum_age>5 Months</minimum_age>
	<maximum_age>6 Months</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>